CELZ News - Candlesense

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies,...

How does the efficacy and safety data released so far compare to the standard of care and to other emerging regenerative therapies? What are the expected pricing and reimbursement scenarios for a DDD therapy in the U.S. market? How might the news affect short‑interest and options activity on CELZ?

Clinical trials

10 days ago